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Abstract
Background: The co-occurrence of two or more medical conditions in the same individual is not uncommon. If
disability-adjusted life year (DALY) calculations are carried out for each condition separately, multimorbidity may
lead to an overestimation of the morbidity component, the Years Lived with Disability (YLD). Adjusting for
comorbidity may be straightforward if all symptoms have same onset and duration; however, when the comorbid
health states occur at different time points, an analytical solution to the comorbidity problem becomes more
complex. The aim of this study was to develop an individual-based modelling (IBM) approach to adjust incidence-
based disease burden estimation for multimorbidity that allows simulating hypothetical individuals and tracking
their disease history, including possible comorbidities, over time.
Methods: We demonstrated the IBM approach using an example of external comorbidity, i.e., colon cancer
comorbid with healthcare-associated pneumonia (HAP) and by assuming an independent multiplicative model.
First, each cumulative progression probabilities were converted to a daily transition probabilities. Second, disability
weights for simultaneously experienced health states and duration in each health state were determined. Third,
YLD, adjusted for comorbidity, was calculated at every time step. We simulated a cohort of 1000 colorectal cancer
patients aged 65 years. Ninety-five percent uncertainty intervals around median YLD values were estimated by
Monte Carlo methods.
Results: The median estimated YLD per 1000 cases (due to both cancer and HAP) adjusted for co-morbidity was
545 YLD/1000 (95% interval: 513–585). The impact of not adjusting disability weights for co-existent health states
varied from minimal to small; YLD for colorectal cancer would be overestimated only slightly – by 1.6 YLD/1000 –
by not adjusting for concurrent HAP. YLD for those HAP patients who have concurrent early-stage colorectal cancer
would be overestimated by 2.3 YLD/1000.
Conclusions: The computation of disease burden in the presence of multimorbidity using the incidence-based
DALY approach can be handled through IBM. Our approach can be extended to other, more complicated
multimorbidity scenarios which are responsible for a high current global disease burden, such as tuberculosis and
HIV infection.
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Background
The co-occurrence of two or more medical conditions in
the same individual is not uncommon, especially in the
elderly [1]. In the medical literature, this phenomenon is
often termed multimorbidity. When the focus is on an
index disease, the presence of co-existing condition(s) –
whether or not these are causally related to the index
disease or occur independently – is typically referred to
as comorbidity [2]. If disability-adjusted life year (DALY)
calculations are carried out for each condition separ-
ately, multimorbidity may lead to an overestimation of
the morbidity component, the Years Lived with Disabil-
ity (YLD). Assume, for instance, a patient with simultan-
eous moderate osteoarthritis of the shoulder (disability
weight (DW) = 0.117 [3];) and moderate chronic ob-
structive pulmonary disease (COPD)(DW = 0.225 [3];).
Without adjusting for multimorbidity, the DW for this
patient would implicitly be calculated as the sum of both
DWs, i.e., 0.117 + 0.225 = 0.342. However, assuming that
DWs can simply be summed to capture the level of dis-
ability experienced by a patient with multimorbidity, is
not necessarily correct [4, 5]. Furthermore, additivity
could lead to a multimorbid DW that is larger than one,
i.e., a situation “worse than death”.
Various other methods have been described to account
for multimorbidity and overcome the limitations of the
additive approach [5]. In the maximum limit or worst
case approach, the multimorbid DW is set equal to the
highest DW of the individual conditions. For our patient,
this would result in a multimorbid DW of 0.225; i.e., that
of COPD. In the multiplicative approach, the multimor-
bid DW is calculated as: 1 −∏i(1 −DWi), with DWi the
individual DW. For our patient, this would result in a
DW of 1 − (1–0.117)(1–0.225) = 0.316. Assuming that
the multiplicative approach is approximately correct and
that the additive approach overestimates experienced
disability, it is easy to see that the degree by which dis-
ability, and thus YLD, is overestimated using the additive
approach grows with the severity of either comorbid
condition (the difference between the two approaches is
greatest when the DWs approach 1.0). Underestimation
of true experienced severity by both the additive and
multiplicative approaches is also possible.
Dealing with comorbidity: prevalence vs. incidence-based
models
In addition to a model for combining DWs for a given
patient, dealing with comorbidity also requires epi-
demiological data on the co-occurrence of disease.
Ideally, this information should come from a
population-based health survey. However, due to the
large number of possible causes of ill health (if there are
h diseases/conditions that can co-occur, then there are
2h – 1 occurrence/co-occurrences possible), it is
practically impossible to measure all possible diseases
and conditions in a population sample [6]). In absence
of such information, a pragmatic solution was proposed
in the GBD 2010 study by introducing prevalence-based
YLDs, which made it feasible to correct for multimor-
bidity. The GBD authors used microsimulation methods
to estimate the prevalence of multimorbidity from the
prevalence of the individual conditions, within each age
and sex stratum [7, 8].
The original formulation of the DALY metric, how-
ever, prescribed an incidence perspective for calculating
YLDs [9]. Using this perspective, YLDs measure future
health losses due to current exposures, and is therefore
often the preferred approach for quantifying the burden
of infectious diseases [10, 11]. However, accounting for
multimorbidity in incidence-based disease models is
more complicated – because the onset times and dur-
ation of diseases/conditions do not normally coincide –
and no practical solutions have been provided.
Multimorbidity in disease models may occur in various
forms. We propose a pragmatic classification, into in-
ternal and external comorbidity. Internal comorbidity
refers to co-occurrence of health states within the same
disease model, while external comorbidity refers to co-
occurrence of multiple diseases (i.e., not within the same
model). For instance, the co-occurrence of different
health states associated with the same infectious disease
would be considered internal comorbidity, while the co-
occurrence of the health states of the infectious disease
with the health states of a non-communicable disease
occurring in the same patient, would be considered ex-
ternal comorbidity. The distinction between both de-
pends on the definition of what comprises a disease
model (for instance, both the infectious and non-
communicable disease in our example can have a joint
risk factor, and could thus be combined in a risk factor-
based disease model), and is as such arbitrary. Nonethe-
less, it is an operational definition that is useful to
demonstrate possibilities and corresponds to current lit-
erature on disease burden calculations [12].
The main objective of this paper is to develop a
method to adjust incidence-based disease burden esti-
mation for multimorbidity that can be applied to two or
more co-existing health states. To correctly compute
YLD in the presence of comorbidity, we propose an
individual-based modelling approach. We illustrate this
approach by calculating YLD for a worked example of
‘external comorbidity’, i.e., colon cancer complicated by
healthcare-associated pneumonia (HAP). Although years
of life lost (YLL) is the second necessary component of
the DALY measure, in the current paper we restrict to
YLD because distinct analysis strategies are required to
partition YLL among competing mortality risks in the
case of multimorbidity [13].
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Methods
Approach for dealing with comorbidity using incidence
-based DALY
Within a given disease model, multiple health states may
occur in sequence (for instance, an acute followed by a
chronic disease stage) or in parallel – with the latter be-
ing either mutually exclusive (for instance, multiple se-
verity levels), or not (for instance, multiple symptoms).
Using the terminology introduced before, this may give
rise to a situation of internal comorbidity. Figure 1 gives
a schematic representation of how health states can
overlap in time for a single individual and the conse-
quence for experienced disability. If, continuing with the
example above, during the entire time that a patient suf-
fered from COPD he/she also had osteoarthritis, then
YLD for osteoarthritis would be overestimated by 8%
(1–0.342/0.316) if the co-existence of COPD was as-
sumed to have an additive effect on severity, compared
with adjustment using the multiplicative approach.
By definition, comorbidity occurs for health states that
overlap in time and that are not mutually exclusive.
Adjusting for comorbidity may be straightforward if all
symptoms have same onset and duration. For instance,
following severe sepsis due to healthcare-associated
pneumonia (HAP) infection (Fig. 2), one may develop
one or more lifelong disabilities. Indeed, in such cases,
comorbidity occurs throughout the rest of the patient’s
life (in our example: post-traumatic stress disorder
(PTSD), cognitive impairment, physical (mobility) im-
pairment, and renal failure). Therefore, to compute YLD
the model requires only the probabilities of disease oc-
currence and possible correlations, the disability weight
of each health state, and a choice to be made on how to
appropriately combine disability weights.
When the comorbid health states occur at different
time points, an analytical solution to the comorbidity
problem becomes more complex, especially if one wants
to consider variability and/or uncertainty in the calcula-
tions. Indeed, the adjustment requires knowledge on the
specific time points when multiple conditions co-exist.
To address this problem, we adopt an individual-based
model (IBM) approach, which allows the simulation of a
hypothetical cohort of individuals and the tracking of
their disease history, including possible comorbidities,
over time. We demonstrate this approach using an ex-
ample of external comorbidity, i.e., colorectal cancer
complicated by HAP.
Example IBM for external comorbidity
There are two health states standardly assumed within
the clinical progression pathway for cancers that respond
to treatment: Diagnosis and Control/management. For
non-responders, there are additional two states: Pre-ter-
minal (or metastatic) and Terminal. We simplified the
pathway to two states: Diagnosis/therapy and Pre-ter-
minal/terminal states (Fig. 2). For colorectal cancer, the
probability of cure is age-dependent, but for simplicity
we set this parameter to a single value, 56% [16]. This
means the probability of death from cancer was (100–
56%) = 44%. In addition, we did not consider possible se-
quelae occurring among cured patients.
The risk of acquiring HAP was restricted to the Diag-
nosis/therapy state only, when cancer patients would be
initially admitted to hospital. This was not easily
Fig. 1 Hypothetical time course of experienced departure from full health (disability weight) for an individual in two health states with delayed
onset. The dashed line indicates the additive approach, and the solid line indicates the multiplicative approach to experienced disability
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obtainable from the literature; for our worked example
we set this parameter to 12%, which is the prevalence of
all HAIs among patients in the specialty Transplant/can-
cer surgery from a point prevalence survey in the Euro-
pean acute-care setting, 2011–2012 [17]. This is higher
than earlier reports of HAP incidence (e.g., crude rate of
6.1/1000 discharges [18];). Table 1 details all colorectal
cancer disease model parameters.
We adopted a previously published clinical path-
way progression model for HAP [14], which
consists of the health states Symptomatic infection
followed by either, recovery, Severe sepsis or death.
Patients who had progressed to Severe sepsis can
develop the life-long (and non-mutually exclusive)
sequelae PTSD, Cognitive impairment, and/or Renal
failure. Following Severe sepsis, all patients develop
Physical impairment (Fig. 2 and Table A2). Al-
though intervals/ranges were available for many
model parameters, for simplicity we used only point
estimates.
Fig. 2 (Upper panel) Simplified clinical progression pathway for colorectal cancer. Health states are indicated by boxes, with relative box lengths
indicating average duration in that health state. (Lower panel) Clinical progression pathway for healthcare-associated pneumonia infection
(adapted from [14, 15]), showing the six relevant health states as filled boxes
Table 1 Results of individual-based modelling of worked example of external comorbidity
Disease [− health state] Adjusted YLD/1000
cases
(95% UI)
Unadjusted YLD/1000
cases
(95% UI)
Overestimation of
YLD
(95% UI)
Difference in YLD/1000
cases
Colorectal cancer (All health states) 471.7 (447.8–496.8) 473.3 (449.2–498.9) 0.3% 1.6
– Diagnosis/therapy only 309.4 (291.8–329.9) 310.5 (292.8–331.1) 0.4% 1.1
– Pre-terminal/ terminal only 163.5 (147.4–178.7) 164.0 (148.0–179.2) 0.3% 0.5
HAP co-existent with colorectal cancer (All health
states)
73.0 (51.4–98.1) 75.3 (52.8–102.0) 3.0% 2.3
– Symptomatic infection 0.4 (0.3–0.5) 0.4 (0.3–0.5) 9.9% 0.0
– Severe sepsis, septic shock 1.1 (0.8–1.5) 1.4 (0.9–1.9) 25.5% 0.3
– PTSD 17.4 (8.1–28.8) 18.1 (8.4–29.8) 3.9% 0.7
– Cognitive impairment 14.4 (8.7–21.1) 14.8 (8.9–21.7) 3.0% 0.4
– Physical impairment 36.2 (28.0–45.4) 36.7 (28.4–46.0) 1.4% 0.5
– Renal failure & renal replacement therapy 4.2 (0–13.8) 4.5 (0–4.5) 7.9% 0.3
Note. Results compare Years Lived with Disability (YLD) per 1000 cases for colorectal cancer adjusted and unadjusted for comorbidity due to healthcare-associated
pneumonia (HAP), and also HAP (among patients with colorectal cancer), both adjusted and unadjusted for comorbidity, in terms of absolute and relative
differences in YLD
PTSD post-traumatic stress disorder, UI uncertainty interval
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Progression probabilities
The probability of each of these combinations of health
states is the product of the probability of observing (or
not) of each individual health state – at least, if
independence between health states is assumed. We
modelled comorbidity assuming an independent multi-
plicative model, i.e., the probability of simultaneously ex-
periencing a combination of health states is the product
of the probabilities of experiencing each of the individual
health states, regardless if the health states are part of
the clinical progression pathway for the same disease/
agent or are part of different disease pathways.
Because our IBM uses a time step of 1 day, we first
needed to convert each cumulative progression probabil-
ity to a daily rate. For example, in the HAP disease
model, the health state Severe sepsis develops following
Symptomatic infection with a cumulative probability of
0.39 (Table A2), meaning that 39% of all individuals pro-
gress to this health state. We converted this cumulative
probability to a daily rate, based on the mean duration
in the Symptomatic infection health state of 0.025 years
(=9.1 days), using the standard formula:
rsepsis ¼ − log 1−0:39ð Þ=9:1
and then to a daily transition probability for use in the
IBM:
1− exp −rsepsis
 
The daily transition probability for this example is
0.0529. Point estimates for the cumulative probabilities
of developing all other health states were similarly con-
verted to daily transition probabilities. The cumulative
probability of cancer patients acquiring HAP infection
during the Diagnosis/therapy state, 0.12, was converted
in the same way, yielding a daily probability of HAP of
0.00016.
Determining disability weights for simultaneously
experienced health states
We define the disability weight for a time step as a func-
tion of all of the health states experienced by the individ-
ual at that time step. For the adjusted method, we use
the multiplicative approach (i.e.: 1 −∏i(1 −DWi)) as de-
scribed previously [5, 19]. To permit comparison to a
measure of YLD unadjusted for comorbidity, we adopted
the published disability weights for each health state in-
stead of adjusting weights according to the formula in
the previous sentence, and so effectively assumed addi-
tivity in experienced disability for co-existing health
states.
Disability weights for the individual health states for
colorectal cancer were obtained from Salomon et al. [3],
and weights for HAP were taken from Burden of
Communicable Diseases in Europe (BCoDE) reports and
other sources [14, 15, 20] (Tables A1 and A2).
Duration in each health state
For colorectal cancer, the mean duration of the Diagno-
sis/therapy state was set to 1.08 years [16]; as the median
survival time for patients who die from this cancer is 1.6
years [16], the mean duration of the Pre-terminal/ter-
minal state was set to (1.6–1.08) = 0.52 years). Mean du-
rations for the various HAP health states were taken
from the BCoDE project reports [14, 15] (see Table A2).
YLD computation
YLD, adjusted for comorbidity, was calculated at every
time step i as in the following, where Zi is the maximum
number of co-existent health states at time step i (which
can vary as the prevalence and nature of multimorbidity
is time-dependent), ns,i is the number of individuals in
state s at time step i, and DWadj,i is the disability weight
at time step i adjusted using the multiplicative method
(above):
DWad j:i ¼ 1−
Y
s
1−DWsð Þ
To allocate disability among the set of health states ex-
perienced by an individual at time i, DWadj,i is propor-
tionally redistributed to these health states:
DWadj;s:i ¼ DWadj:i DWs;iXZ
s¼1
DWs;i
Adjusted YLD is then calculated as:
YLDadj;i ¼
XZi
s¼1
ns;i  DWadj;s;i
YLD, unadjusted for comorbidity, was similarly com-
puted at each time step i, except the unadjusted disabil-
ity weight, DW, was used:
YLDunadj;i ¼
XZi
s¼1
ns;i  dws
Simulation procedure and R code
We simulated a cohort of 1000 colorectal cancer pa-
tients aged 65 years; residual life expectancy at this age
was fixed at 20 years. Onset of cancer disease burden
was defined as the moment of diagnosis. The onset of
possible HAP infection was stochastically simulated for
each individual as a draw from a Bernoulli distribution
at each time-step during the Diagnosis/therapy health
state only. From the onset of HAP, random draws from
the relevant distributions were made at each time step
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to simulate progression from SI to Sepsis and from SI to
death. Progression to one or more of the four long-term
sequelae could occur after the offset of Sepsis. Note that
in the IBM approach HAP health states can also be ex-
perienced simultaneously; for instance PTSD and Phys-
ical impairment. All patients progressed through the
colorectal cancer clinical pathway; random Bernoulli
draws were made to determine if a patient was cured, or
progressed to the Pre-terminal/terminal health state and
then to death (Fig. 2). The principal outcome was de-
fined as the absolute difference between comorbidity-
unadjusted and adjusted and YLD among the entire co-
hort, per disease, and per health outcome; the relative
difference was also computed.
Ninety-five percent uncertainty intervals – accounting
for stochasticity – around median YLD per 1000 cases
were estimated by Monte Carlo methods; namely, by re-
peating the simulation 500 times and calculating the me-
dian and 2.5th and 97.5th percentiles of the resulting
distribution of simulated YLD values. Simulations were
conducted in the R statistical programming environ-
ment, version 3.5.1 [21]. R code to implement both IBM
simulations is provided in Additional file 1.
Sensitivity analysis
As there is uncertainty regarding the selected values of
all model parameters, although largely taken from previ-
ous research, it is of interest to explore to what degree
the choice of parameter value impacts on the results, by
considering alternative values to the point estimate. We
therefore carried out one-way sensitivity analyses for
each of five parameters (the progression probabilities to
Sepsis and to death following SI with HAP, the risk of
developing HAP among patients with colorectal cancer,
the progression probability from Diagnosis/therapy to
Pre-terminal/terminal health state, and the total dur-
ation in all health states of colorectal cancer), by testing
the effect of a parameter value either 20% lower or 20%
greater than the ‘baseline’ value (i.e., the point estimate),
and re-running the simulation.
Results
The median estimated cumulative total YLD per 1000
cases (due to both cancer and HAP) – representing the
future disease burden ‘assigned’ to the affected cohort of
1000 colorectal cancer patients under the incidence-
based DALY approach – adjusted for co-morbidity was
545.3, and was reasonably stable over 500 simulations
(95% uncertainty interval of 513.1–584.6).
Cumulative total YLD was overestimated by 4.1 per
1000 cases (relative measure: 0.7%) if no disability ad-
justment is made (median YLD of 549.4 for the un-
adjusted measure; see Fig. A1). Figure 3 shows (highly
overlapping) estimated YLD for colorectal cancer over
time comparing unadjusted and adjusted variants of
the model, and estimated YLD for HAP (as occurring
in cancer patients) both adjusted and unadjusted for
comorbidity with cancer. Prevalence over time, for all
health states of both cancer and HAP is depicted in
Fig. A2.
Table 1 compares comorbidity-adjusted YLD with YLD
computed when not adjusting for disease co-existence, for
each disease and health state separately. The morbidity bur-
den computed for cancer among a cohort of colorectal can-
cer patients in which HAP was co-existent was slightly
higher (1.6 YLD/1000 cases; relative 0.3%) when not adjust-
ing for comorbidity (median YLD of 471.7 and 473.3, for
unadjusted and adjusted measures, respectively). The mor-
bidity burden attributable to HAP among a cohort of can-
cer patients in which HAP co-occurred was also slightly
overestimated, by 2.3 YLD/1000 (relative 3.0%), if disability
weights were not adjusted for comorbidity (median YLD of
Fig. 3 (Upper panel) Years lived with disability (YLD) per 1000 cases
per day, for colorectal cancer over time, unadjusted or adjusted for
co-occurrence with healthcare-associated pneumonia (HAP), for a
simulated cohort of cancer patients from age 65 to 85 years. (Lower
panel) Comorbidity-adjusted YLD per 1000 cases per day, for HAP,
for 120 HAP infections occurring among a simulated 1000 patient
cohort. Adjusted YLD in both panels is overlaid with YLD computed
using the unadjusted approach; note that the two series in the
upper panel almost completely overlap. Values represent means
over 500 simulations
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73.0 and 75.3 for unadjusted and adjusted measures, re-
spectively). This overestimation was mostly driven by the
PTSD and Physical impairment health states (0.7 and 0.5
higher YLD/1000 for unadjusted measures, respectively;
Table 1).
The results of the one-way sensitivity analysis indi-
cated that the selected parameter value for the five pa-
rameters explored only minimally affected the outcome
measure (the difference in absolute YLD per 1000 cases
between adjusted and unadjusted models (Fig. A3). The
largest impact was observed for the progression prob-
ability from symptomatic infection with HAP to severe
sepsis, which when set to 20% lower than the baseline
value, a difference of 2.5 in absolute YLD/1000 cases be-
tween model variants was observed.
Discussion
We have demonstrated that individual-based modelling
offers a practical means to deal with multimorbidity in the
calculation of YLD using the incidence-based approach to
disease burden estimation. The IBM method proved use-
ful, firstly for demonstrating that failing to adjust for a sin-
gle comorbid condition can lead to overestimation of
disease burden, and secondly for providing a practical im-
plementation for ‘real-world’ disease burden estimation
using the incidence-based approach. This means that
given suitable and unbiased data on the distribution of
multimorbidity (which may be challenging in itself, as is
the case for all data required for DALY estimation), the
totality of disease burden in a given patient population
can be correctly computed. With slight modifications, the
IBM code can be used for other conditions (such as injur-
ies), and to address issues such as individual heterogeneity
in progression probabilities [22].
For our external comorbidity example, the impact of
not adjusting disability weights for co-existent health
states varied from minimal to small; YLD for colorectal
cancer would be overestimated only slightly – by 1.6
YLD/1000 cases – by not adjusting for concurrent HAP.
YLD for those HAP patients who have concurrent early-
stage colorectal cancer would also be slightly overesti-
mated, by 2.3 YLD/1000 cases. Importantly, failing to
adjust for internal comorbidity also leads to an overesti-
mated burden attributable to HAP (because of poten-
tially overlapping long-term sequelae), irrespective of the
presence of an underlying condition such as cancer.
The impact of adjustment on the disease burden
among patients with multimorbidity is expected to be
very small in the case of internal comorbidity. This is
because the distribution of risk over the health states
of a given disease potentially occurring simultaneously
tends to be heavily skewed; most states have a very
low risk of occurrence (at least for infectious diseases
[23]). In our worked example, the long-term sequelae
of HAP constitutes a case of internal comorbidity, as
an individual can occupy one or more of the four
health states following Severe sepsis simultaneously.
Previous approaches for adjusting health burden mea-
sures for comorbidity include regression analysis to decom-
pose the effects of multimorbidity on HRQoL [24, 25].
Similar decomposition methods have been used to examine
the contribution made by causes of disability to differences
in healthy life expectancy [26, 27] or disability prevalence
[28]. Unlike the classical DALY approach, these methods
allow for a “background” burden, i.e., disability in subjects
without a reported disease. Unfortunately, decomposition
methods only permit the study of the contribution of mul-
tiple causes to overall health; they do not allow one to cal-
culate a DW for an arbitrary set of conditions. While
adjusting DWs for co-occurring health states has straight-
forward application within prevalence-based DALY
estimation [7, 19], and recent work has dealt with internal
co-morbidity within the incidence-based DALY framework
[12], to our knowledge there has been no previous efforts
to develop a general-purpose method for incidence-based
DALYs involving external co-morbidity using individual-
based modelling.
Limitations
Our approach used a multiplicative approach to com-
bine DWs for temporally overlapping health states. Al-
though this approach has the desired mathematical
property of not resulting in comorbid DWs higher than
1, there is little empirical evidence on the validity of this
model. For purposes of the worked example, we did not
consider uncertainty in any parameter values assumed
(we used point estimates only), but the one-way sensitiv-
ity analysis indicated that the conclusions held given
changes of plus or minus 20% of the baseline parameter
value.
In addition to an appropriately adjusted multimorbid
DW, calculating YLDs also requires data on the preva-
lence or incidence of the multimorbid condition. In the
GBD studies, the prevalence of multimorbidity was esti-
mated by assuming independence between the preva-
lence of the individual diseases [7, 8]. Assuming
independence for our worked example would mean that
the prevalence of the given multimorbidity would equal
the product of the prevalence of colorectal cancer and
the prevalence of HAP, which would appear to be im-
plausible as the risk of HAP is higher for ICU than non-
ICU patients [29], for instance. This could lead to an
overestimation of the burden of the individual diseases.
Murray et al. [7] argue that the error associated with the
independence assumption is minimal when this assump-
tion is applied within each specific age–sex group. How-
ever, there is little evidence to support this assumption.
Data on the correlations between occurrence of different
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conditions, e.g., quantified using odds ratios [19], would
help to assess this independence assumption.
Because we restricted our simulation to YLD, we did
not consider how to handle a potentially increased mortal-
ity rate if a person has two or more co-morbid conditions.
This primarily would have an impact on the computation
of YLL, but could also affect YLD by truncating the time
lived with long-term sequelae. Similarly, our approach
does not currently handle the situations in which a second
condition influences the duration of one or more health
states of the first, or in which a second condition influ-
ences the clinical pathway of the first (i.e., by incurring
long-term disability; for instance a lower respiratory tract
infection worsening COPD). However, the IBM could be
extended to take such interdependencies into account.
Lacking suitable data on the rate of HAP among can-
cer patients undergoing diagnosis/therapy, the parameter
value we selected for the cumulative risk of HAP for pa-
tients in this health state is meant to illustrate the
difference between adjustment/non-adjustment only.
However, sensitivity analysis indicated that results were
only slightly dependent on the precise value chosen. Fi-
nally, the impact of comorbidity adjustments is variable,
and depends on the epidemiological context and the ad-
justment methodology chosen [19]). It is likely that such
adjustments may have a greater impact on patient-level
compared with population-level burden estimates – a
significant difference may be seen in selected patient
groups such as the elderly with a high prevalence of
multi-morbidity but not when considering the national
population – and consequently have a larger impact on
health economic evaluations.
For didactic purposes, our simulation contained many
simplifications compared with DALY computation in
practice: only two diseases, probability of cure was inde-
pendent of age, residual life expectancy was set at 20
years for every cohort member, and mortality rates were
assumed unaffected by the presence of comorbidity.
Nevertheless, the IBM approach can incorporate all of
these complexities.
For analysts using the incidence-based DALY ap-
proach, we suggest implementing the proposed methods
for certain diseases (for which suitable comorbidity
prevalence data – in particular, data on the co-
occurrence probabilities of comorbid conditions – are
available) in parallel to routine burden calculation activ-
ities, so that results using the proposed approach can be
compared to the findings obtained using standard meth-
odology. This will assist in ascertaining the expected
magnitude of differences in YLD estimates realised in
‘real-world’ practice between comorbidity-adjusted and
unadjusted approaches, and whether there are any impli-
cations for disease ranking in terms of burden that may
be used by policy-makers for prioritisation.
Conclusions
The computation of disease burden in the presence of
multimorbidity using the incidence-based DALY ap-
proach can be handled through IBM. In our worked ex-
ample, adjusting for comorbidity produced YLD
estimates that only slightly differed from unadjusted esti-
mates. We purposely demonstrated our approach a
using simple, yet realistic scenario. Our approach can be
extended to other, more complicated multimorbidity
scenarios which are responsible for a high current global
disease burden, such as tuberculosis and HIV infection
[30]. Further investigation of the current approach using
such diseases is required to determine if comorbidity ad-
justment for disease burden computation will have rele-
vance for public health decision-making.
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